ScoreWhy is BioNexus Gene Lab Corp. ?
1
Poor Management Efficiency with a low ROE of 5.57%
- The company has been able to generate a Return on Equity (avg) of 5.57% signifying low profitability per unit of shareholders funds
2
The company has declared Negative results for the last 3 consecutive quarters
- NET PROFIT(9M) At USD -1.86 MM has Grown at -48.58%
- OPERATING CASH FLOW(Y) Lowest at USD -2.83 MM
- DEBT-EQUITY RATIO (HY) Highest at -39.77 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -21.45%, its profits have fallen by -134%
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 14.90% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -21.45% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is BioNexus Gene Lab Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
BioNexus Gene Lab Corp.
-21.45%
0.32
1133.91%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
59.71%
EBIT Growth (5y)
-175.79%
EBIT to Interest (avg)
-0.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.17
Tax Ratio
0.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.79%
ROCE (avg)
5.92%
ROE (avg)
5.57%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.59
EV to EBIT
-0.79
EV to EBITDA
-0.89
EV to Capital Employed
0.30
EV to Sales
0.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-38.41%
ROE (Latest)
-33.38%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET PROFIT(HY)
Higher at USD -1.3 MM
RAW MATERIAL COST(Y)
Fallen by -36.99% (YoY
-10What is not working for the Company
NET PROFIT(9M)
At USD -1.86 MM has Grown at -48.58%
OPERATING CASH FLOW(Y)
Lowest at USD -2.83 MM
DEBT-EQUITY RATIO
(HY)
Highest at -39.77 %
Here's what is working for BioNexus Gene Lab Corp.
Net Profit
Higher at USD -1.3 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -36.99% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for BioNexus Gene Lab Corp.
Operating Cash Flow
Lowest at USD -2.83 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -39.77 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
